Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: The way forward

American Journal of Cardiovascular Drugs

Volumn 2, Issue 5, 2002, Pages 287-296

  Terra, Steven G ^a   Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARDIOVASCULAR AGENT; CARVEDILOL; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLIZING ENZYME; ETANERCEPT; FOLIC ACID; GLYCOPROTEIN P; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; ORAL CONTRACEPTIVE AGENT; PROPRANOLOL; QUINIDINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TIMOLOL; TRASTUZUMAB; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; DYSLIPIDEMIA; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HERITABILITY; HUMAN; HUMAN GENOME; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; LUNG DISEASE; PATHOGENICITY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0036399958     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202050-00001     Document Type: Article

References (90)

1. McPherson JD, Marra M, Hillier L, et al. A physical map of the human genome. Nature 2001; 409: 934-41
2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91
3. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39
4. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 2001; 52: 345-7
5. Roses AD. Pharmacogenetics. Hum Mol Genet 2001; 10: 2261-7
6. Brookes AJ. The essence of SNPs. Gene 1999; 234: 177-86
7. Single nucleotide polymorphisms for biomedical research [online]. The SNP Consortium Ltd. Available from URL: http://snp.cshl.org [Accessed 2002 June 25]
8. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101-21
9. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
10. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9
11. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8
12. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8
13. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9
14. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55
15. Miners JO, Coulter S, Birkett DJ, et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267-70
16. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57: 518-24
17. Labbe L, O'Hara G, Lefebvre M, et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther 2000; 68: 44-57
18. Lai ML, Wang SL, Lai MD, et al. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995; 58: 264-8
19. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-7
20. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-8
21. Matheny CJ, Lamb MW, Brouwer KR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96
22. Perry Jr HM, Tan EM, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970; 76: 114-25
23. Woosley RL, Drayer DE, Reidenberg MM, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-9
24. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT); Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8
25. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1 Suppl. 1): 8S-21S
26. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42
27. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-7
28. Idle JR, Corchero J, Gonzalez FJ. Medical implications of HGP's sequence of chromosome 22 [letter]. Lancet 2000; 355 (9200): 319
29. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-8
30. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50: 308-13
31. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000; 1: 85-99
32. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74
33. Burgess JK, Lindeman R, Chesterman CN, et al. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995; 91: 761-6
34. Brandt IT, Isenhart CE, Osborne JM, et al. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72
35. Carlsson LE, Santoso S, Baurichter G, et al. Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 1998; 92: 1526-31
36. Wheeler GL, Braden GA, Bray PF, et al. Reduced inhibition by abciximab in platelets with the P1A2 polymorphism. Am Heart J 2002; 143: 76-82
37. Undas A, Sanak M, Musial J, et al. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982-3
38. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285: 906-13
39. Glueck CJ, Wang P, Fontaine RN, et al. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999; 84: 549-54
40. Pullin CH, Ashfield-Watt PA, Burr ML, et al. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. J Am Coll Cardiol 2001; 38: 1799-805
41. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103: 1644-8
42. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 691-6
43. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-87
44. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101: 1366-71
45. Bray PF, Cannon CP, Goldschmidt-Clermont P, et al. The platelet P1(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347-52
46. de Maat MP, Kastelein JJ, Jukema JW, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen, REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18: 265-71
47. de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852-6
48. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis: The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93
49. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7
50. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3
51. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial; EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998; 47: 1507-11
52. Ohmichi N, Iwai N, Uchida Y, et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10: 951-5
53. Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14: 427-32
54. Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies 1. Kidney Int 2000; 57: 274-81
55. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56: 2173-80
56. Mukae S, Aoki S, Itoh S, et al. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36: 127-31
57. Puckett BJ, Pauly DF, Zineh I, et al. Beta-adrenergic receptor polymorphisms and antihypertensive response to beta-blocker therapy [abstract]. Clin Pharmacol Ther 2002; 71: P2
58. Jia H, Hingorani AD, Sharma P, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34: 8-14
59. Turner ST, Schwartz GL, Chapman AB, et al. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-43
60. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7
61. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-9
62. Glorioso N, Manunta P, Filigheddu F, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34: 649-54
63. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410: 289-302
64. Evans AE, Poirier O, Kee F, et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Q J Med 1994; 87: 211-4
65. Zee RY, Lou YK, Griffiths LR, et al. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992; 184: 9-15
66. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4
67. Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28: 162-7
68. Sanderson JE, Young RP, Yu CM, et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. Am J Cardiol 1996; 77: 1008-10
69. Mizuiri S, Hemmi H, Inoue A, et al. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron 1997; 75: 310-4
70. Veterans Administration Cooperative Study Group on Antihypertensive Agents, Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, II: results of long-term therapy, Veterans Administration Cooperative Study Group on Antihypertensive Agents. JAMA 1982; 248: 2004-11
71. Veterans Administration Cooperative Study Group on Antihypertensive Agents, 38. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, I: results of short-term titration with emphasis on racial differences in response, Veterans Administration Cooperative Study Group on Antihypertensive agents. JAMA 1982; 248: 1996-2003
72. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-21
73. Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670-4
74. Humma LM, Puckett BJ, Richardson HE, et al. Effects of beta(1)-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001; 88: 1034-7
75. Manunta P, Burnier M, D'Amico M, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694-7
76. Poch E, Gonzalez D, Giner V, et al. Molecular basis of salt sensitivity in human hypertension: evaluation of Renin-Angiotensin-aldosterone system gene polymorphisms. Hypertension 2001; 38: 1204-9
77. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa P1A2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 1142-7
78. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4
79. Kastrati A, Schomig A, Seyfarth M, et al. P1A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005-10
80. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 528-31
81. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703
82. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31
83. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
84. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled trial. JAMA 2002; 288: 321-33
85. Tollman P, Guy P, Altshuler J, et al. A revolution in R&D: how genomics and agenetics are transforming the biopharmaceutical industry [online]. Available from URL: http://www.bcg.com [Accessed 2002 Feb 18]
86. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-4
87. Lee RT. Functional genomics and cardiovascular drug discovery. Circulation 2001; 104: 1441-6
88. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol 2001; 28: 3-11
89. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358-61
90. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-6